Phosphodiesterases: Genes and their variants, inhibitors and potential therapeutic applications

Expert Review of Endocrinology and Metabolism

Volumn 6, Issue 4, 2011, Pages 497-499

  Faucz, Fabio Rueda ^a   Bertollo De Alexandre, Rodrigo ^a,b   Stratakis, Constantine A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

endocrine tumors; PDE; PDE inhibitors; phosphodiesterase; secondary messengers

Indexed keywords

ALDOSTERONE; CYCLIC AMP; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PHOSPHODIESTERASE 11A; PHOSPHODIESTERASE 2A; PHOSPHODIESTERASE 4B; PHOSPHODIESTERASE 5A; PHOSPHODIESTERASE V INHIBITOR; PHOSPHODIESTERASE VI; PROTEIN P53; RAF PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ASTHMA; BREAST TUMOR; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON ADENOCARCINOMA; DEPRESSION; DNA POLYMORPHISM; EDITORIAL; ENDOCRINE TUMOR; EYE DISEASE; GENE INTERACTION; HEART FAILURE; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PULMONARY HYPERTENSION; RHEUMATOID ARTHRITIS; RNA SPLICING; SCHIZOPHRENIA;

EID: 79960166725     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.11.48     Document Type: Editorial

References (33)

1. Halpin DM. ABCD of the phosphodiesterase family: interaction and differential activity in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 3(4), 543-561 (2008).
2. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76, 481-511 (2007).
3. Nikolaev VO, Gambaryan S, Engelhardt S, Walter U, Lohse MJ. Real-time monitoring of the PDE2 activity of live cells: hormone-stimulated cAMP hydrolysis is faster than hormone-stimulated cAMP synthesis. J. Biol. Chem. 280(3), 1716-1719 (2005).
4. Fatemi SH, King DP, Reutiman TJ, et al. PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophr. Res. 101(1-3), 36-49 (2008).
5. Huang SH, Pittler SJ, Huang X, Oliveira L, Berson EL, Dryja TP. Autosomal recessive retinitis pigmentosa caused by mutations in the a subunit of rod cGMP phosphodiesterase. Nat. Genet. 11(4), 468-471 (1995).
6. Luo HR, Wu GS, Dong C, et al. Association of PDE11A global haplotype with major depression and antidepressant drug response. Neuropsychiatr. Dis. Treat. 5, 163-170 (2009).
7. Horvath A, Boikos S, Giatzakis C, et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat. Genet. 38(7), 794-800 (2006). (Pubitemid 43980600)
8. Horvath A, Giatzakis C, Robinson- White A, et al. Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population. Cancer Res. 66(24), 11571-11575 (2006). (Pubitemid 46094164)
9. Horvath A, Korde L, Greene MH, et al. Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors. Cancer Res. 69(13), 5301-5306 (2009).
10. Faucz FR, Horvath A, Rothenbuhler A, et al. Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer. J. Clin. Endocrinol. Metab. 96(1), E135-E140 (2011).
11. Schmidt CJ, Chapin DS, Cianfrogna J, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J. Pharmacol. Exp. Ther. 325(2), 681-690 (2008). (Pubitemid 351574819)
12. Threlfell S, Sammut S, Menniti FS, Schmidt CJ, West AR. Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation. J. Pharmacol. Exp. Ther. 328(3), 785-795 (2009).
13. Verhoest PR, Chapin DS, Corman M, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol- 3-yl)-phenoxymethyl]-quinoline (PF- 2545920) for the treatment of schizophrenia. J. Med. Chem. 52(16), 5188-5196 (2009).
14. Dandrea MR, Qiu Y, Haynes-Johnson D, Bhattacharjee S, Kraft P, Lundeen S. Expression of PDE11A in normal and malignant human tissues. J. Histochem. Cytochem. 53(7), 895-903 (2005). (Pubitemid 40923465)
15. Luedders DW, Muenz BM, Li F, et al. Role of cGMP in sildenafil-induced activation of endothelial Ca2+-activated K+ channels. J. Cardiovasc. Pharmacol. 47(3), 365-370 (2006). (Pubitemid 44309688)
16. Hotston M, Shukla N, Bloor J, Persad R, Jeremy JY. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int. 98(6), 1331-1332 (2006). (Pubitemid 44721256)
17. Wang C. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr. Opin. Urol. 20(1), 49-54 (2010).
18. Wong P, Lawrentschuk N, Bolton DM. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds. Curr. Opin. Urol. 19(1), 7-12 (2009).
19. Zhu B, Vemavarapu L, Thompson WJ, Strada SJ. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J. Cell. Biochem. 94(2), 336-350 (2005). (Pubitemid 41420312)
20. Tinsley HN, Gary BD, Keeton AB, et al. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol. Cancer Ther. 8(12), 3331-3340 (2009).
21. Cook AL, Haynes JM. Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal 16(2), 253-261 (2004). (Pubitemid 37441272)
22. Hood J, Granger HJ. Protein kinase G mediates vascular endothelial growth factor-induced Raf-1 activation and proliferation in human endothelial cells. J. Biol. Chem. 273(36), 23504-23508 (1998). (Pubitemid 28417542)
23. Pyriochou A, Zhou Z, Koika V, et al. The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway. J. Cell Physiol. 211(1), 197-204 (2007). (Pubitemid 46363910)
24. Griffith OW, Stuehr DJ. Nitric oxide synthases: properties and catalytic mechanism. Annu. Rev. Physiol. 57, 707-736 (1995).
25. Zhao Z, Francis CE, Welch G, Loscalzo J, Ravid K. Reduced glutathione prevents nitric oxide-induced apoptosis in vascular smooth muscle cells. Biochim. Biophys. Acta 1359(2), 143-152 (1997). (Pubitemid 27507816)
26. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am. J. Physiol. 267(5 Pt 1), C1405-C1413 (1994).
27. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65, 1-52 (2001).
28. Weeks JL 2nd, Zoraghi R, Francis SH, Corbin JD. N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization. Biochemistry 46(36), 10353-10364 (2007). (Pubitemid 350067628)
29. Porst H, Hell-Momeni K, Buttner H. [Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil]. Urologe A 48(11), 1318, 1320-1319 (2009).
30. Desiniotis A, Schafer G, Klocker H, Eder IE. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A. Int. J. Cancer 126(3), 775-789 (2010).
31. Merkle D, Hoffmann R. Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. Cell Signal 23(3), 507-515 (2011).
32. Maioli E, Torricelli C, Fortino V. Functional interactions of protein kinase A and C in signalling networks: a recapitulation. Cell Mol. Life Sci. 63(6), 637-641 (2006).
33. Yadav V, Denning MF. Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Mol. Carcinog. 50(5), 346-352 (2011).